LEADS BIOLABS-B (09887) announced that the first patient has been successfully enrolled in a Phase II clinical study evaluating VELISIN™ (PD-L1/4-1BB bispecific antibody, Opatisumimab, LBL-024) for the treatment of first-line esophageal squamous cell carcinoma. This open-label, multicenter Phase II clinical study is led by Professor Lin Shen, Director of Peking University Cancer Hospital, and is being conducted simultaneously at multiple hospitals across the country. The trial aims to evaluate the efficacy and safety of Opatisumimab in treating patients with first-line esophageal squamous cell carcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments